Effects of CCR5-Δ32, CCR2-64I, and SDF-1 3′ a alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data

Annals of Internal Medicine

Volumn 135, Issue 9, 2001, Pages 782-795

  Ioannidis, J P A ^a   Rosenberg, P S ^a   Goedert, J J ^a   Ashton, L J ^a   Benfield, T L ^a   Buchbinder, S P ^a   Coutinho, R A ^a   Eugen Olsen, J ^a   Gallart, T ^a   Katzenstein, T L ^a   Kostrikis, L G ^a   Kuipers, H ^a   Louie, L G ^a   Mallal, S A ^a   Margolick, J B ^a   Martinez, O P ^a   Meyer, L ^a   Michael, N L ^a   Operskalski, E ^a   Pantaleo, G ^a   Rizzardi, G P ^a   Schuitemaker, H ^a   Sheppard, H W ^a   Stewart, G J ^a   Theodorou, I D ^a   Ullum, H ^a   Vicenzi, E ^a   Vlahov, D ^a   Wilkinson, D ^a   Workman, C ^a   Zagury, J F ^a   O'Brien, T R ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; STROMAL CELL DERIVED FACTOR 1; ALPHA CHEMOKINE; CHEMOKINE RECEPTOR; MONOCYTE CHEMOATTRACTANT PROTEIN 1 RECEPTOR; RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; GENETIC RISK; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SEROCONVERSION; ALLELE; CLINICAL TRIAL; GENETICS; HETEROZYGOTE; METABOLISM; MORTALITY; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ALLELES; CHEMOKINES, CXC; DISEASE PROGRESSION; HETEROZYGOTE; HIV INFECTIONS; HIV-1; HUMANS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; REGRESSION ANALYSIS; RNA;

EID: 0035818402     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-135-9-200111060-00008     Document Type: Article

References (47)

1. Quantitative synthesis in systematic reviews
2. Practical methodology of meta-analyses (overviews) using updated individual patient data
3. Summing up evidence: One answer is not always enough
4. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
5. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene
6. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development study, Multicenter AIDS Cohort study, Multicenter Hemophilia Cohort study, San Francisco City Cohort, ALIVE study
7. HIV-1 infection in a man homozygous for CCR5 delta 32
8. Chemokine receptors and genetic variability: Another leap in HIV research
9. HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type
10. Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: Relationship with viral load
11. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression
12. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: Studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk
13. Association between CCR5 genotype and the clinical course of HIV-1 infection
14. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals
15. Increased frequency of CCR-5 delta 32 heterozygotes among longterm non-progressors with HIV-1 infection
16. Genetic polymorphism of CCR5 gene and HIV disease: The heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort
17. A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness
18. Distinctive effects of CCR5, CCR2, and SDFI genetic polymorphisms in AIDS progression
19. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression
20. No evidence for an effect of the CCR5 delta32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users
21. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development study (HGDS), Multicenter AIDS Cohort study (MACS), Multicenter Hemophilia Cohort study (MHCS), San Francisco City Cohort (SFCC), ALIVE study
22. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression
23. CCR2 chemokine receptor and AIDS progression
24. Chemokine receptor CCR2b 64I polymorphism and its relation to CD4 T-cell counts and disease progression in a Danish cohort of HIV-infected individuals. Copenhagen AIDS cohort
25. CCR2 polymorphism and HIV disease. Swiss HIV Cohort
26. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation
27. Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4
28. CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function
29. Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains
30. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype
31. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE study, Hemophilia Growth and Development study (HGDS), Multicenter AIDS Cohort study (MACS), Multicenter Hemophilia Cohort study (MHCS), San Francisco City Cohort (SFCC)
32. The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection
33. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1 -infected individuals
34. CC-chemokine receptor variants, SDF-1 polymorphism, and disease progression in 720 HIV-infected patients. SEROCO Cohort. Amsterdam Cohort Studies on AIDS
35. Shorter survival of SDF1-3′A/3′A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection
36. Genetic effects on HIV disease progression
37. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes
38. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome
39. Regression models and life tables
40. The statistical basis of meta-analysis
41. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort study
42. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
43. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
44. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy
45. Association of the CCR5delta32 mutation with improved response to antiretroviral therapy
46. Cancer: What should be done?
47. The future of genetic studies of complex human diseases